Loading...
Antiretroviral protease inhibitors (PIs) show activity against Plasmodium falciparum in vitro, likely because of biochemical similarities between plasmodial and HIV proteases. To evaluate whether this activity translates into a reduced risk for childhood malaria, investigators randomized 176 HIV-infected children in Uganda (age range, 6 months to 5 years) to receive either lopinavir/ritonavir or a nonnucleoside reverse transcriptase inhibitor (NNRTI), each together with two nucleosides. Participants also received insecticide-treated bed nets, multivitamins, and daily cotrimoxazole prophylaxis. Those who developed uncomplicated malaria received artemether-lumefantrine.
During 162 person-years of follow-up, 285 new episodes of malaria occurred…